Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report questions Hims' ability to turn customer acquisition into profitability, but recent financial data shows promising revenue and gross profit growth. While Hims may not have a strong brand equity or an impenetrable moat, its approach and million paying subscribers make it a compelling investment.

Hims & Hers: Myopic Shorts, Absurdly Cheap

The Beauty Health Company

Beauty stocks have not been pretty this year. Cosmetics retailer Ulta Beauty Inc. NASDAQ: ULTA and Estee Lauder Co. NYSE: EL shares are trading down 12.3% and 38.7%, respectively.

2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally

Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SPAC. The company is targeting lofty growth targets for years to come and has plans to expand in many new markets while maintaining gross profits near 80%. The current valuation is rather low at a P/S of just 1.8. The risk-reward profile for an entry point seems very favourable at the moment.

The Market Is Wrong On Hims & Hers Health

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced Great Place To Work® and Fortune magazine named the company on the 2023 Fortune Best Workplaces in Health Care™ List. The Best Workplaces in Health Care award is based on analysis of survey responses from over 208,000 employees from Great Place To Work Certified™ companies in the healthcare industry. Earning a spot means that Hims & Hers is.

Hims & Hers Named on Fortune Media and Great Place to Work's 2023 Best Workplaces in Health Care List

Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%.

Is This Underrated SPAC Deal Stock a No-Brainer Buy?

The market for weight management could be worth close to $300 billion by the end of the decade. Hims & Hers is planning to launch a weight-loss business by January.

This Fast-Growing Company Is the Latest to Launch a Weight-Loss Business

Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories such as heart health and weight management. We believe HIMS stock is undervalued, and current prices present a buying opportunity.

Hims & Hers: Buying With Both Fists (Double Rating Upgrade)

Q2 Revenue beat analyst estimates by $3M. Gross Margin improved despite price cuts. Management raised guidance by $20M, which also beat estimates by $19M.

Hims & Hers: Divergence Between Fundamentals And Valuation

HIMS & Hers Health is performing well, beating guidance and recording positive developments in most metrics. The company is cash flow positive, debt-free, and experiencing peak popularity among search engine users. My updated DCF model indicates over 3.4x potential from current levels, signaling a buying opportunity.

Hims & Hers: The Current Weakness Creates A Buying Opportunity

Hims & Hers Health keeps turning in stellar operating results. But shares have slid 30% over the past few months.

Could Hims & Hers Health Stock Help You Become a Millionaire?

This potential multibagger stock is being underappreciated by the market. Here's why Hims & Hers stock is a buy right now.

Is Hims & Hers Health Stock a Must Buy Under $10?

Hims & Hers (NYSE: HIMS) stock price bounced back after the company published strong results and boosted its forward guidance. The shares closed the day at $7.90 and then surged by over 19% to $9.20.

Hims & Hers stock price has gone parabolic: Is it a good buy?

Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President, Investor Relations Andrew Dudum - Co-Founder & Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities Michael Cherny - Bank of America Glen Santangelo - Jefferies Jungwon Kim - Cowen Jonathan Young - Credit Suisse Jailendra Singh - Truist Securities George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Ivan Feinseth - Tigress Financial Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Second Quarter 2023 Earnings Conference Call.

Hims & Hers Health, Inc. (HIMS) Q2 2023 Earnings Call Transcript

Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.10 per share a year ago.

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

Hims & Hers Health Inc. HIMS, -3.07% shares rallied nearly 13% in the aftermarket Monday after the telehealth company reported a narrower-than-expected loss for its second quarter and revenue that was above expectations. Hims & Hers lost $7.2 million, or 3 cents a share, in the quarter, compared with $19.7 million, or 10 cents a share, in the second quarter of 2022.

Hims & Hers stock jumps 13% after narrower loss in Q2

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the second quarter ended June 30, 2023. “This quarter marks a significant turning point for Hims & Hers, where step-change progress was made in transforming our company from an access-oriented company, towards a platform offering a personalized patient experience,” said Andrew Dudum, co-founder and CEO.

Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

Hims & Hers Health has lagged the market for the past couple of months. The business is executing well and is unprofitable as it is investing heavily to grow revenue instead of earnings. A bargain valuation and strong growth outlook make shares a no-brainer for long-term investors in my view.

Hims & Hers Health: Giving Investors Another Bite At The Apple

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced a new approach to enable providers to personalize sexual health treatment for men that also supports cardiovascular health. Through Heart Health by Hims, providers will be able to personalize treatments to combine active ingredients found in clinically proven medications to address multiple conditions in one pill, demonstrating Hims & Hers'.

Hims & Hers Expands Into Cardiovascular Health with New Dual-Action Capabilities

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2023 financial results after the market closes on Monday, August 7, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refer.

Hims & Hers to Announce Second Quarter 2023 Financial Results on August 7, 2023

Spruce Capital Management issued a short report on Hims & Hers Health, Inc., but the call actually only forecast downside risk to $5. The health and wellness company continues to grow at a fast clip while expanding the market opportunity beyond the initial ED category. The stock rallied on the news, with Hims already beaten down this year and trading at a cheap valuation.

Hims & Hers: Market Blows Off Short Report

Teladoc

Teladoc's ambition to disrupt the healthcare industry with technology and virtual care looked to be working during the pandemic - its shares rose >700%. Meanwhile, Hims & Hers launched a more pragmatic platform and IPO'd in 2021 via a SPAC. Teladoc's share price came crashing down to earth as it became obvious that its subscribers rarely used the services on offer.

Hims & Hers Vs. Teladoc: Different Approaches To 'Telemedicine' - But Only One Is Working

I recommend a buy rating due to Hims & Hers Health's strong growth, expanding EBITDA margins, and potential in the growing telehealth market. I see room for further margin expansion as HIMS increases fulfillment capacity through affiliated pharmacies. Despite competition from larger players, the Company's strong balance sheet and growing profitability position it well for future growth and potential acquisitions.

Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong

Hims & Hers Health stock has fallen since its last earnings report. Wall Street could be misinterpreting the company's high marketing spend.

The More This Potential Multibagger Stock Drops, The More I Buy

Viking Therapeutics

Hims & Hers has a booming telemedicine business that could grow by 57% this year. Viking Therapeutics has a promising pipeline that features a couple of potential blockbuster drugs.

2 Hot Stocks Up 30% This Year That Wall Street Thinks Can Still Go Higher

Marqeta

Today we dive into a pocket of the stock market that many investors like to own as part of diversified portfolios: cheap stocks trading for $10 a share or less. Along with the cheap price tag, the stocks we explore today boast high Zacks Ranks given their improving earnings outlooks.

News for Hims & Hers Health Stock (HIMS)